Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges Authors: Esteban Ciliberti, Marta Nerone, Vincenza Ricco, Hui-Ming Lin, Frederik Marmé, Cristiana Sessa, Isabelle Ray Coquard, Kathleen N. Moore, Ilaria Colombo Published: 2026 ABSTRACT SummaryAntibody–drug conjugates (ADCs), which are tumor-targeting antibodies conjugated with cytotoxic chemotherapy agents, have emerged as a promising therapeutic approach in gynaecological cancers. Gynaecologicaal tumor-associated antigens targeted by ADCs include folate receptor-α (FRα), HER2, TROP2, tissue factor (TF), CDH6, CLDN6, B7–H4, B7–H3 and NaPi2b. Currently, three ADCs are clinically available for the treatment of gynaecological cancers: Mirvetuximab soravtansine for FRα-positive ovarian cancer, Tisotumab vedotin (targeting TF) for cervical cancer, and Trastuzumab deruxtecan for HER2-positive solid tumors. Various stages of investigation of ADCs as single agent or in combination treatments are ongoing with promising early signs of efficacy. Upon positive results from phase III trials, new treatment options will be available to reshape the standard of care of gynaecological malignancies and improve patients’ outcome. This review summarizes the major clinical studies of ADCs in ovarian, endometrial and cervical cancer, and explores the main challenges related to their use in clinical practice. Search strategy and selection criteriaData for this review were identified by searches of Pubmed, references from relevant articles, proceedings from major oncology conferences (ASCO, SGO, ESMO, ESMO Gynaecological cancers, ESMO ASIA, ESGO), and ClinicalTrials.gov. The search terms were “ADCs”, “gynaecological cancers”, “ovarian cancer”, “endometrial cancer”, “cervical cancer”. Only articles published in English between 1996 and 2025 were included. Search strategy and selection criteria Data for this review were identified by searches of Pubmed, references from relevant articles, proceedings from major oncology conferences (ASCO, SGO, ESMO, ESMO Gynaecological cancers, ESMO ASIA, ESGO), and ClinicalTrials.gov. The search terms were “ADCs”, “gynaecological cancers”, “ovarian cancer”, “endometrial cancer”, “cervical cancer”. Only articles published in English between 1996 and 2025 were included. Introduction Gynaecological cancers represent a significant global health burden among women.1 Their incidence and mortality rates are projected to increase in the coming years.2 Therapeutic options are limited for advanced or recurrent disease, thus effective intervention strategies are urgently needed.3, 4, 5 Antibody–drug conjugates (ADCs) are emerging as a particularly promising therapy in advanced gynaecological cancers. This revolutionary class of drugs showed clinical efficacy in various cancers, with 15 ADCs being approved over the past decade and more than 210 currently under clinical investigation.6 The rationale for their use is underpinned by the identification of cancer-specific cell-surface antigens, opening new avenues for biomarker-tailored therapy. This review summarizes the current clinical landscape of ADCs in ovarian, endometrial and cervical cancers, highlighting data from both early and late-phase trials. Efficacy and safety outcomes of the most promising agents are presented, including a discussion on the future perspectives of this evolving therapeutic field. ADC structure and targets ADCs are composed of monoclonal antibodies with chemically-linked cytotoxic drug molecules (the payload). The antibody is typically a humanized immunoglobulin G designed to target a cell surface tumor antigen that is minimally or not expressed by non-malignant tissues. This enables the selective delivery of the cytotoxic payload to cancer cells with reduced off-target systemic toxicity. Payloads consist of highly potent agents such as DNA-damaging topoisomerase I inhibitors (e.g., camptothecin derivatives such as exatecans and SN-38) or microtubule inhibitors (e.g., auristatins such as MMAE and MMAF and maytansinoids like DM1 and DM4). From a clinical perspective, the payload acts as the primary determinant of the adverse event profile because off-target toxicities of the ADC frequently mirror those of the free cytotoxic agent. For instance, ADCs carrying microtubule inhibitors are frequently associated with peripheral neuropathy and thrombocytopenia. Conversely, topoisomerase I inhibitors exhibit a toxicity profile characterized by gastrointestinal events, hematological toxicities, and alopecia. The physicochemical properties of the payload—specifically membrane permeability—have also direct implications on the efficacy of the ADC, particularly when confronting tumor heterogeneity. The linker that connects the cytotoxic payload to the antibody is integral to its release at the target sites.7 Cleavable linkers release their payload upon chemical degradation (e.g., pH sensitive) or enzymatic degradation (e.g., cleavage by lysosomal proteases), thus facilitating the release of hydrophobic, membrane-permeable payloads. Non-cleavable linkers require complete degradation of the antibody to release the payload, which often results in charged molecules that are unable to passively diffuse out of the cell. The stability of the linker also modulates the clinical toxicity profile. A delicate equilibrium exists: unstable linkers lead to premature payload release in the plasma, resulting in systemic adverse events akin to standard chemotherapy. However, excessively stable linkers prolong the circulation of the intact ADC, thereby increasing non-specific uptake (e.g., via macropinocytosis) in healthy tissues. This mechanism has been linked to distinct off-target toxicities.8 Upon ADC binding to its target antigen on the cancer cell membrane, the complex is predominantly internalized via receptor-mediated endocytosis.9 The payload exerts its cytotoxic effect when it is released inside the cell, and is able to act on adjacent cells if it diffuses across the cell membrane (depending on the linker and payload hydrophobicity). Emerging evidence has revealed this ‘bystander effect’ to be crucial in determining efficacy in the context of tumor heterogeneity, as uptake of the ADC by target-positive tumor cells will also affect adjacent target-negative tumor cells.10,11 The average number of payload molecules conjugated to each antibody (Drug-to-Antibody Ratio, DAR), adds an additional layer of complexity. From a pharmacodynamic standpoint, a higher DAR would theoretically confer an increased therapeutic advantage. However, because most cytotoxic payloads are inherently lipophilic, a high DAR fundamentally alters the antibody scaffold surface chemistry. This shift drives hydrophobicity-based aggregation, resulting in accelerated clearance by the reticuloendothelial system and thus impaired antigen binding.12 Crucially, the emergence of hydrophilic linkers has mitigated this structural conundrum. By masking the payload's lipophilicity, these novel linkers enable the stable conjugation of higher drug loads (e.g., DAR 8) without precipitating rapid clearance, thereby decoupling payload potency from pharmacokinetic instability. A brief overview of the main tumor-associated antigens targeted by ADCs in gynaecological cancers is presented below and in Fig. 1.•FRα (FOLR1, folate receptor alpha): mediates the cellular uptake of folate; highly expressed on the surface of cancer cells including ovarian and endometrial; associated with poor survival outcomes13; target of Mirvetuximab soravtansine (MIRV), Luveltamab tazevibulin (STRO-002), Rinatabart sesutecan (Rina-S), Torvutatug samrotecan (AZD5335) and, Sofetabart mipitecan (LY4170156).•HER2 (human epidermal growth factor receptor 2; ERBB2, erb-b2 receptor tyrosine kinase 2): regulator of cell growth and survival14; overexpression drives uncontrolled cellular proliferation; involved in initiation and progression of various cancers including gynaecological cancers14; target of Trastuzumab deruxtecan (T-DXd), Trastuzumab pamirtecan (DB-1303/BNT323).•TROP2 (Trophoblast cell-surface antigen 2): cell surface transmembrane glycoprotein; crucial role in calcium signalling and cell cycle-related pathways; highly expressed in gynaecological cancers15; target of Sacituzumab Govitecan (SG), Datopotamab deruxtecan (Dato-DXd), Sacituzumab tirumotecan (Sac-TMT), SHR-A1921.•CDH6 (Cadherin-6): single-transmembrane protein involved in brain and kidney development; expressed in various cancers; overexpression in up to 85% of advanced ovarian tumors was associated with poor prognosis16,17; target of Raludotatug deruxtecan (R-DXd).•CLDN6 (Claudin-6): integral membrane protein highly expressed during embryonic development; minimal/undetectable expression in non-malignant adult tissue; abnormally expressed in multiple cancers including ovarian and endometrial18,19; implicated in tumor initiation, progression, and metastasis20; target of TORL-1–23.•B7–H4 (B7-homolog 4): transmembrane glycoprotein with immunoregulatory role in cancer; overexpressed in solid tumors including ovarian cancer; dampens immune responses, especially T-cell activity (theoretically, ADCs targeting B7–H4 can kill tumor cells directly and also restore anti-tumor immunity)21; target of GSK5733584 (GSK’584, HS-20089), Puxitatug samrotecan (AZD8205), Sigvotatug vedotin (SGN-B7H4V).•B7–H3 (B7-homolog 3; CD276): tumor-expressing immune checkpoint inhibitor; associated with poor prognosis in cervical cancer22; target of DB-1311/BNT324.•Mesothelin: a membrane-bound glycoprotein with limited expression in normal tissues and high expression in several cancers; associated with poor prognosis in ovarian cancer23; target of Anetumab ravtansine.24•NaPi2b (SLC34A2, solute carrier family 34 member 2): sodium-dependent phosphate transporter; expressed in various solid tumors, including ovarian cancer25; target of Lifastuzumab vedotin (LIFA),26 Upifitamab rilsodotin (UpRi), TUB-040.•Nectin-4: cell adhesion molecule with restricted tissue distribution; oncogenic driver in various carcinomas including ovarian and cervical cancer; target of 9MW2821.27•Tissue factor (F3, coagulation factor III): cell surface glycoprotein involved in the initiation of blood coagulation cascades; abnormally expressed in cervical cancers where its high expression is associated with a negative prognosis28; target of Tisotumab vedotin (TV).Fig. 1Overview of the main tumor-associated antigens targeted by ADCs and of the structure of ADCs at more advance stage of investigation in gynaecological cancers. ADC, Antibody drug conjugate; CDH6, Cadherin-6; DAR, Drug-to-Antibody Ratio; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; IgG1, Immunoglobulin 1; TF, Tissue Factor; TROP2, Trophoblast Cell Surface Antigen. •FRα (FOLR1, folate receptor alpha): mediates the cellular uptake of folate; highly expressed on the surface of cancer cells including ovarian and endometrial; associated with poor survival outcomes13; target of Mirvetuximab soravtansine (MIRV), Luveltamab tazevibulin (STRO-002), Rinatabart sesutecan (Rina-S), Torvutatug samrotecan (AZD5335) and, Sofetabart mipitecan (LY4170156). FRα (FOLR1, folate receptor alpha): mediates the cellular uptake of folate; highly expressed on the surface of cancer cells including ovarian and endometrial; associated with poor survival outcomes13; target of Mirvetuximab soravtansine (MIRV), Luveltamab tazevibulin (STRO-002), Rinatabart sesutecan (Rina-S), Torvutatug samrotecan (AZD5335) and, Sofetabart mipitecan (LY4170156). •HER2 (human epidermal growth factor receptor 2; ERBB2, erb-b2 receptor tyrosine kinase 2): regulator of cell growth and survival14; overexpression drives uncontrolled cellular proliferation; involved in initiation and progression of various cancers including gynaecological cancers14; target of Trastuzumab deruxtecan (T-DXd), Trastuzumab pamirtecan (DB-1303/BNT323). HER2 (human epidermal growth factor receptor 2; ERBB2, erb-b2 receptor tyrosine kinase 2): regulator of cell growth and survival14; overexpression drives uncontrolled cellular proliferation; involved in initiation and progression of various cancers including gynaecological cancers14; target of Trastuzumab deruxtecan (T-DXd), Trastuzumab pamirtecan (DB-1303/BNT323). •TROP2 (Trophoblast cell-surface antigen 2): cell surface transmembrane glycoprotein; crucial role in calcium signalling and cell cycle-related pathways; highly expressed in gynaecological cancers15; target of Sacituzumab Govitecan (SG), Datopotamab deruxtecan (Dato-DXd), Sacituzumab tirumotecan (Sac-TMT), SHR-A1921. TROP2 (Trophoblast cell-surface antigen 2): cell surface transmembrane glycoprotein; crucial role in calcium signalling and cell cycle-related pathways; highly expressed in gynaecological cancers15; target of Sacituzumab Govitecan (SG), Datopotamab deruxtecan (Dato-DXd), Sacituzumab tirumotecan (Sac-TMT), SHR-A1921. •CDH6 (Cadherin-6): single-transmembrane protein involved in brain and kidney development; expressed in various cancers; overexpression in up to 85% of advanced ovarian tumors was associated with poor prognosis16,17; target of Raludotatug deruxtecan (R-DXd). CDH6 (Cadherin-6): single-transmembrane protein involved in brain and kidney development; expressed in various cancers; overexpression in up to 85% of advanced ovarian tumors was associated with poor prognosis16,17; target of Raludotatug deruxtecan (R-DXd). •CLDN6 (Claudin-6): integral membrane protein highly expressed during embryonic development; minimal/undetectable expression in non-malignant adult tissue; abnormally expressed in multiple cancers including ovarian and endometrial18,19; implicated in tumor initiation, progression, and metastasis20; target of TORL-1–23. CLDN6 (Claudin-6): integral membrane protein highly expressed during embryonic development; minimal/undetectable expression in non-malignant adult tissue; abnormally expressed in multiple cancers including ovarian and endometrial18,19; implicated in tumor initiation, progression, and metastasis20; target of TORL-1–23. •B7–H4 (B7-homolog 4): transmembrane glycoprotein with immunoregulatory role in cancer; overexpressed in solid tumors including ovarian cancer; dampens immune responses, especially T-cell activity (theoretically, ADCs targeting B7–H4 can kill tumor cells directly and also restore anti-tumor immunity)21; target of GSK5733584 (GSK’584, HS-20089), Puxitatug samrotecan (AZD8205), Sigvotatug vedotin (SGN-B7H4V). B7–H4 (B7-homolog 4): transmembrane glycoprotein with immunoregulatory role in cancer; overexpressed in solid tumors including ovarian cancer; dampens immune responses, especially T-cell activity (theoretically, ADCs targeting B7–H4 can kill tumor cells directly and also restore anti-tumor immunity)21; target of GSK5733584 (GSK’584, HS-20089), Puxitatug samrotecan (AZD8205), Sigvotatug vedotin (SGN-B7H4V). •B7–H3 (B7-homolog 3; CD276): tumor-expressing immune checkpoint inhibitor; associated with poor prognosis in cervical cancer22; target of DB-1311/BNT324. B7–H3 (B7-homolog 3; CD276): tumor-expressing immune checkpoint inhibitor; associated with poor prognosis in cervical cancer22; target of DB-1311/BNT324. •Mesothelin: a membrane-bound glycoprotein with limited expression in normal tissues and high expression in several cancers; associated with poor prognosis in ovarian cancer23; target of Anetumab ravtansine.24 Mesothelin: a membrane-bound glycoprotein with limited expression in normal tissues and high expression in several cancers; associated with poor prognosis in ovarian cancer23; target of Anetumab ravtansine.24 •NaPi2b (SLC34A2, solute carrier family 34 member 2): sodium-dependent phosphate transporter; expressed in various solid tumors, including ovarian cancer25; target of Lifastuzumab vedotin (LIFA),26 Upifitamab rilsodotin (UpRi), TUB-040. NaPi2b (SLC34A2, solute carrier family 34 member 2): sodium-dependent phosphate transporter; expressed in various solid tumors, including ovarian cancer25; target of Lifastuzumab vedotin (LIFA),26 Upifitamab rilsodotin (UpRi), TUB-040. •Nectin-4: cell adhesion molecule with restricted tissue distribution; oncogenic driver in various carcinomas including ovarian and cervical cancer; target of 9MW2821.27 Nectin-4: cell adhesion molecule with restricted tissue distribution; oncogenic driver in various carcinomas including ovarian and cervical cancer; target of 9MW2821.27 •Tissue factor (F3, coagulation factor III): cell surface glycoprotein involved in the initiation of blood coagulation cascades; abnormally expressed in cervical cancers where its high expression is associated with a negative prognosis28; target of Tisotumab vedotin (TV). Tissue factor (F3, coagulation factor III): cell surface glycoprotein involved in the initiation of blood coagulation cascades; abnormally expressed in cervical cancers where its high expression is associated with a negative prognosis28; target of Tisotumab vedotin (TV). Overview of the main tumor-associated antigens targeted by ADCs and of the structure of ADCs at more advance stage of investigation in gynaecological cancers. ADC, Antibody drug conjugate; CDH6, Cadherin-6; DAR, Drug-to-Antibody Ratio; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; IgG1, Immunoglobulin 1; TF, Tissue Factor; TROP2, Trophoblast Cell Surface Antigen. ADCs in ovarian cancer Ovarian cancer ranks in eighth place both in terms of global incidence and cancer mortality for female cancers.1 The standard of care for ovarian cancer is upfront surgery followed by post-operative platinum-based chemotherapy. In recent years, maintenance strategies employing anti-angiogenic agents and PARP inhibitors have significantly improved patient prognosis. However, there are limited therapeutic options when patients develop resistance to platinum-based chemotherapy, with a 5-year survival of only 20% for stage IV disease.29 Among the three gynaecological cancers, ovarian cancer has received the most attention in ADC research in pre-clinical and clinical settings.30 Ovarian cancer antigens targeted by ADCs include FRα, HER2, TROP2, CDH6, claudin-6, B7–H4, B7–H3, mesothelin, or NaPi2b (Table 134,36,37,40,46,48,51,52,54, and Figure S1).Table 1Efficacy and safety of selected ADCs in ovarian cancer.aWhen available.ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, folare receptor alfa; HER2, human epidermal growth factor 2; NA, not available; NaPi2b, sodium-dependent phosphate transport protein 2B; ORR, objective response rate; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2. Sample sizes follow the cited published data and may refer to either the specified subpopulation or the overall cohort.According to ClinicalTrials.gov (accessed on 27 November 2025). Table 1Efficacy and safety of selected ADCs in ovarian cancer.aWhen available.ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, folare receptor alfa; HER2, human epidermal growth factor 2; NA, not available; NaPi2b, sodium-dependent phosphate transport protein 2B; ORR, objective response rate; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2. Sample sizes follow the cited published data and may refer to either the specified subpopulation or the overall cohort.According to ClinicalTrials.gov (accessed on 27 November 2025). Efficacy and safety of selected ADCs in ovarian cancer. aWhen available. ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, folare receptor alfa; HER2, human epidermal growth factor 2; NA, not available; NaPi2b, sodium-dependent phosphate transport protein 2B; ORR, objective response rate; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2. Sample sizes follow the cited published data and may refer to either the specified subpopulation or the overall cohort. According to ClinicalTrials.gov (accessed on 27 November 2025). FRα-targeted ADCs Clinical trials on FRα-targeted ADCs in ovarian cancer were initially conducted on patients with various levels of FRα expression, given the potential for a bystander effect on FRα-negative cells. Mirvetuximab soravtansine (MIRV) is composed of a humanized anti-FRα antibody and a DM4 payload (maytansinoid tubulin inhibitor) connected through a cleavable linker. The phase III FORWARD I trial comparing MIRV to chemotherapy in platinum-resistant ovarian (PROC) cancer did not meet its primary progression-free survival (PFS) endpoint. This result was largely attributed to the FRα scoring method used for patient selection.31 The 10 × scoring method (≥50% of tumor cells with staining at 10 × magnification) allowed inclusion of patients with relatively low FRα expression. Subsequent exploratory rescoring using the more selective PS2+ method (combining both the percentage of positive cells and the intensity of staining on tissue) demonstrated that the 10 × method underestimated the efficacy of mirvetuximab by including tumors with lower biomarker expression, thereby leading to inferior clinical outcomes. These findings led to the adoption of the PS2+ scoring system in the design of subsequent trials (single-arm phase II SORAYA, randomized phase III MIRASOL), with the aim of investigating MIRV in a better selected population. In SORAYA, MIRV demonstrated significant activity and favorable tolerability in patients with platinum resistant (PROC), FRα-high tumors (up to three lines of prior therapies including bevacizumab). In these patients, the objective response rate (ORR) with MIRV was 32.4%, median duration of response (DOR) was 6.9 months, and median overall survival (OS) was around 15.0 months.32,59 The MIRASOL trial, which evaluated MIRV against a single agent chemotherapy (investigator's choice) in patients with PROC confirmed significant improvement in survival outcomes with MIRV (median PFS 5.62 vs 3.98 months, hazard ratio (HR) 0.72; median OS 16.46 vs 12.75 months, HR 0.67; ORR 42.3% vs 15.9%).33 These results led to FDA and EMA approval for use of MIRV in patients with high FRα PROC who have received up to three prior lines of systemic therapy. Consequently, MIRV was investigated next in the platinum-sensitive recurrent (PSOC) setting as single or combination therapy. The phase II single-arm PICCOLO trial assesed MIRV as third or later line of treatment in patients with FRα-positive recurrent PSOC and achieved its primary endpoint with an ORR 51.9% and median PFS 6.93 months.35 In the phase Ib/II FORWARD II trial, MIRV plus bevacizumab showed promising efficacy (ORR 69%, PFS 13.3 months) and safety in a subset of patients with FRα-high PSOC.60 The randomized phase III GLORIOSA trial (NCT05445778) will evaluate MIRV plus bevacizumab vs bevacizumab alone as maintenance therapy in patients with FRα-high PSOC following second-line platinum-based doublet chemotherapy plus bevacizumab.61 The overall safety profile of MIRV is favourable with the most commonly reported treatment-related adverse events (TRAEs) being low-grade ocular toxicity, fatigue, gastrointestinal toxicity (constipation, nausea), hematologic abnormalities and neurosensory symptoms. Notably, in the MIRASOL trial, more than 50% of patients receiving MIRV underwent dose modifications due to adverse events; however, this was associated with lower rates of treatment discontinuation, with sustained improvements in both PFS and OS compared to investigator's choice of chemotherapy.62 Despite its significant clinical activity in ovarian cancer, MIRV will only benefit one third of patients with PROC according to the low prevalence of high FRα expression. Thus, the focus is now on developing FRα-targeted ADCs that are effective even with lower FRα expression. An example is Luveltamab tazevibulin (STRO-002), a FRα-targeting ADC with a stable cleavable linker to an antitubulin payload (3-aminophenyl hemiasterlin). In a phase I dose expansion study, the ORR in unselected patients treated with STRO-002 was comparable to those with high FRα expression (positive in ≥25% cancer cells; ORR 31.7% vs 37.5%).63 In the phase II part of the phase II/III REFRαME-O1 trial which included PROC patients with FRα expression of ≥25%, the ORR was 32% and disease control rate (DCR) was 96% with STRO-002 treatment.64 Main toxicities observed were neutropenia, fatigue and gastrointestinal symptoms. However, STRO-002 development was discontinued due to a company strategic decision. Another FRα-targeted ADC, Rinatabart sesutecan (Rina-S), is composed of an anti-FRα antibody, a novel hydrophilic protease-cleavable linker, and a topoisomerase I inhibitor (exatecan) payload. Preliminary results from the ongoing phase I/II PRO1184-001 trial (NCT05579366) indicate promising antitumor activity by Rina-S with an ORR of 50% in patients who were mostly PROC and heavily pretreated. Antitumor responses were observed across all levels of FRα expression, including in patients with undetectable FRα expression.65 Rina-S is currently under investigation in a phase III trial of PROC vs treatment of investigator's choice (NCT06619236). Torvutatug samrotecan (AZD5335) is a novel ADC constructed from a high-affinity anti-FRα antibody and conjugated to a topoisomerase I inhibitor payload. Currently, the phase I/IIa FONTANA trial (NCT05797168) is evaluating AZD5335 as monotherapy or in combination in patients with advanced solid tumors. Preliminary results indicate promising efficacy and a manageable safety profile in PROC treated with AZD5335 (ORR 53.6%); durable activity was observed across all dose levels in both high and low FRα-expressing tumors.66 Sofetabart mipitecan (LY4170156) is another promising anti-FRα ADC combining a linked to exatecan, a topo-I inhibitor, via a proprietary cleavable polysarcosine (PSAR) linker. The phase I trial showed promising clinical activity in heavily pretreated patients across all FRα expression levels and regardless of prior MIRV exposure (ORR was 42% in pts with FRa ≥75% and 50% in pts with FRa <75%).38 The ongoing phase III FRAmework-01 trial will investigate LY4170156 monotherapy in patients with PROC, and in combination with bevacizumab in patients with PSOC (NCT07213804). These preliminary results suggest potential comparable efficacy among the different ADCs targeting FRα in OC. These findings raise important questions regarding optimal agent selection and the sequencing of ADCs with different cytotoxic payloads. The distinct safety and tolerability profiles underscore the need to consider toxicity patterns, in addition to efficacy, when selecting ADCs with different payloads in gynaecological cancers. Results from the ongoing phase 3 trials will be paramount to establish the best treatment options for patients with OC. HER2-targeted ADCs In ovarian cancer, HER2 overexpression was associated with aggressive or high grade histological subtypes and unfavorable prognosis.67,68 Trastuzumab deruxtecan (T-DXd) is a HER2-targeting ADC combining a humanized anti-HER2 antibody conjugated with a potent topoisomerase I inhibitor (DXd) using a cleavable peptide linker that enables bystander effect. Following consistent evidence of antitumor activity of T-DXd in HER2 positive breast cancer, the open-label phase II DESTINY-PanTumor02 basket trial was conducted to evaluate the efficacy and safety of T-DXd in other HER2-expressing solid tumors which included 40 patients with ovarian cancer. ORR for the ovarian cancer cohort treated with T-DXd was 45%, with better efficacy (ORR and PFS) in patients with HER2 3+ expression.39 The safety profile of T-DXd was comparable to that observed in previous pivotal trials of other tumor types. Common grade ≥3 events included hematologic toxicity (neutropenia, anemia), with interstitial lung disease (ILD)/pneumonitis occurring in ∼10–12% of patients. Unlike breast and gastric cancers, there are currently no standardized guidelines for HER2 evaluation in gynaecologic tumors. Given the increasing clinical significance of anti-HER2 ADCs, and to ensure consistent interpretation of clinical trial results, the establishment of standardized HER2 assessment protocols for gynecologic malignancies are highly desirable. Other promising HER2-targeted ADCs with alternative payloads and linkers currently in early clinical development in ovarian cancer include: SYD985 (NCT02277717), GQ1001 (NCT04450732), BNT323/DB-1303 and IBI354 (NCT06834672).41,69, 70, 71 TROP2-targeted ADCs One of the early TROP2 targeted ADCs investigated in ovarian cancer is Sacituzumab Govitecan (SG), composed of a humanized anti-TROP2 antibody linked to govitecan (SN-38, active metabolite of irinotecan, a topoisomerase I inhibitor). In the phase I/II IMMU-132-01 basket trial,43 SG demonstrated efficacy in several cancer subcohorts, including gynaecological tumors; however, no efficacy was observed in a small cohort of patients with ovarian cancer. A phase II study is ongoing to specifically assess its efficacy in PROC (NCT06028932). Moreover, there were high rates of treatment discontinuation due to adverse events. Most common TRAEs were nausea, diarrhea, fatigue, alopecia, and neutropenia. Datopotamab deruxtecan (Dato-DXd) is another TROP2-directed ADC with the topoisomerase I inhibitor deruxtecan conjugated via a cleavable peptide linker, with a DAR lower than SG. Dato-DXd showed a more favourable outcome in patients with ovarian cancer, unselected for TROP2 expression, in the phase II TROPION-PanTumor03 trial (ORR 42.9%, DCR 85.7%, median response time 1.4 months).42 Adverse events included stomatitis, nausea, fatigue, hematologic and ocular toxicities, consistent with known exatecan payload toxicity. Sacituzumab tirumotecan (Sac-TMT) is an ADC composed of an anti-TROP2 antibody combined with a novel camptothecin derivative, also a topoisomerase I inhibitor. In the open-label phase I/II MK-2870-001 trial of locally advanced or metastatic solid tumors refractory to standard therapy, Sac-TMT showed favourable outcome and tolerability in 40 patients with ovarian cancer (ORR 40%, DCR 75%, median PFS 6.0 months, median OS 16.5 months).72 Higher rates of objective response were observed in patients with high TROP2 expression compared to patients with low TROP2 expression (ORR 61.5% vs 27.3%).44 However, the correlation between TROP2 expression and efficacy has not been fully elucidated. In the ovarian cancer population, grade ≥3 TRAEs were 67.5%, with 12.5% leading to treatment discontinuation. The main toxicities reported were hematological and stomatitis. The first-in-human study of SHR-A1921, an ADC composed of a humanized anti-TROP2 antibody linked to a topoisomerase I inhibitor via a cleavable linker, showed manageable safety and encouraging anti-tumor activity in patients with advanced solid tumors regardless of TROP2 expression. Clinical efficacy of SHR-A1921 in the subcohort of PROC was promising (ORR 48.8%, DCR 97.7%). Notably, median PFS was 7.2 months and median OS was not reached, with a 6 months OS rate of 91.9%. The most common grade ≥3 TRAEs were stomatitis (28.3%), anemia and decreased neutrophil count.45 A pivotal phase III trial of SHR-A1921 vs investigator's choice of chemotherapy in PROC is currently ongoing (NCT06394492). CDH6-targeted ADC Raludotatug deruxtecan (R-DXd), an anti-CDH6 antibody linked to the topoisomerase I inhibitor Dxd. R-Dxd demonstrated promising clinical activity in early phase trials of patients with advanced and pretreated ovarian cancer.47 The phase II/III REJOICE-Ovarian01 trial investigating R-Dxd in PROC is currently ongoing (NCT06161025). In the phase II part of the study, R-Dxd showed promising efficacy across all dose levels (ORR 50.5%). Clinically meaningful tumor responses were observed across a range of CDH6 expression, with a positive risk–benefit profile at the 5.6 mg/kg dose, which will be evaluated vs treatment of physician's choice in the phase III part of the trial.73 Common TEAEs reported were nausea, fatigue, vomiting, and diarrhoea. NaPi2B-targeted ADCs Lifastuzumab vedotin (LIFA) consists of a humanized anti-NaPi2b antibody conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker.26 In a phase Ib trial, LIFA in combination with carboplatin (with or without bevacizumab) in patients with recurrent PSOC resulted in a median PFS of 10.7 months with confirmed complete/partial responses in 24 (59%) patients. All patients experienced ≥1 TRAE, with 83% of patients experiencing grade ≥3 TRAEs, and 22% of patients experiencing serious TRAEs.74 In a randomized phase II trial of LIFA vs PLD in patients with PROC, LIFA showed superior activity (ORR 34% vs 15%, median PFS 5.3 vs 3.1 months in the ITT population, and 5.3 months vs 3.4 months in NaPi2b-high patients).57 Upifitamab rilsodotin (UpRi), an anti-NaPi2B ADC with monomethyl auristatin F (MMAF) and a higher DAR than LIFA, showed promising results in a phase I trial of 31 patients with NaPi2b-positive ovarian cancer (ORR 32%, complete response in 2 PSOC patients).75 However, in the phase II UPLIFT trial in patients with PROC, UpRi failed to demonstrate a significant ORR in NaPi2b-positive tumors.58 UpRi also showed an unacceptable safety profile (most common TRAEs included AST increase, nausea, thrombocytopenia, fatigue and anemia), thus UpRi development was discontinued. TUB-040, which has an exatecan payload, demonstrated significant efficacy in heavily pre-treated biomarker-unselected PROC patients (ORR 50% across all dose levels), with tumor responses occurring early and deepening over time. Most common adverse events were neutropenia, anemia, thrombocytopenia, nausea, and diarrhea. There were no reports of clinically relevant bleeding, ocular toxicity or stomatitis. These results have reignited scientific and clinical interest in NaPi2b as a therapeutic target in ovarian cancer.76 Other ADCs Mesothelin-targeted ADC Anetumab ravtansine a fully human IgG1 monoclonal antibody conjugated to DM4,24 showed preliminary anti-tumor activity in its first-in-human phase I study of ovarian cancer, particularly in patients whose tumor expresses mesothelin.77 In a phase Ib study of PROC patients selected for high mesothelin expression, Anetumab ravtansine plus pegylated-liposomal doxorubicin showed an ORR of 42.1% with a median PFS of 8.5 months.55 Despite these promising preclinical data, other trials evaluating Anetumab ravtansine in combination with bevacizumab vs paclitaxel plus bevacizumab failed to demonstrate significant clinical benefit in ovarian cancer, leading to discontinuation of its development.55,56 CLDN6-targeted ADC TORL-1–23 a fully humanized IgG1 monoclonal antibody linked to MMAE, showed high response rates in CLDN6-positive solid tumors, including ovarian cancer, in a phase I trial.49 B7–H4-targeted ADCs Different ADCs are under investigation in early clinical trials. GSK 5733584, composed of a humanized anti–B7–H4 IgG1 antibody linked to the topoisomerase I inhibitor rezetecan via a protease-cleavable linker, displayed preliminary antitumor activity and an acceptable safety profile in a phase I study involving chinese patients with recurrent/metastatic solid tumors unselected for B7–H4 expression. A global phase I trial in patients with advanced solid tumors including PROC and endometrial cancer is currently ongoing (NCT06431594).78 Puxitatug samrotecan (AZD8205), another B7–H4–targeting ADC with a topoisomerase I inhibitor payload, produced partial responses in 20.9% of AZD8205-treated patients with ovarian, breast, or endometrial cancer in a dose-escalation early phase trial (NCT05123482). TEAEs of grade ≥3 occurred in 82.6% of patients (neutropenia 37.0%, anemia 30.4%).50 ADC development in ovarian cancer has yielded clinically meaningful activity, although no clear class-wide advantage in efficacy has yet emerged. Interestingly, for many of these new compounds activity has been demonstrated regardless the level of target expression, making the application of a biomarker-driven approach challenging. Safety profiles differ substantially between agents and remain a key determinant of clinical utility. Optimising target selection and balancing efficacy with tolerability will be essential for a successful integration of ADCs into routine practice. ADCs in endometrial cancer Endometrial cancer is the sixth most commonly diagnosed female cancer globally and ranks 13th place in global female cancer mortality.1 However, it represents the most prevalent gynaecological malignancy in high-income countries and its incidence is increasing.79 The current standard first-line treatment for advanced or recurrent endometrial cancer integrates platinum-based chemotherapy with an immune checkpoint inhibitor. While this combination is beneficial for all patients, its efficacy is most pronounced in tumors with mismatch repair-deficiency (dMMR).3 After failure of platinum-based chemotherapy and immunotherapy, current therapeutic options are limited and ADCs represent a promising new treatment opportunity for patients with endometrial cancer. The main ADCs investigated in endometrial cancer include those that target TROP2, HER2, FRα or B7–H4 (Table 281, 82, 83,86,87 and Figure S1).Table 2Efficacy and safety of the selected ADCs in endometrial cancer.aWhen available.ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2.∗Deveopment has been discontinued.According to ClinicalTrials.gov (accessed on 27 November 2025). Table 2Efficacy and safety of the selected ADCs in endometrial cancer.aWhen available.ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2.∗Deveopment has been discontinued.According to ClinicalTrials.gov (accessed on 27 November 2025). Efficacy and safety of the selected ADCs in endometrial cancer. aWhen available. ADC, antibody drug conjugate; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2. ∗Deveopment has been discontinued. According to ClinicalTrials.gov (accessed on 27 November 2025). TROP2-targeted ADC Overexpression of TROP2 is a feature of aggressive endometrial cancer, including endometrioid and serous carcinoma, thus several ADCs targeting this antigen are in development. In the phase II TROPiCs-03 basket study, SG showed favourable responses (ORR 22%, median DOR 8.8 months) in a cohort of 41 patients with recurrent endometrial cancer, of whom most had prior exposure to checkpoint inhibitors.85 Even though over 70% of participants experienced grade ≥3 adverse events, SG's safety profile was manageable, with low treatment discontinuation rates. Dato-Dxd demonstrated clinically significant outcomes in the TROPION-PanTumor03 study (ORR 27.5%; median PFS of 6.3 months).42 Common adverse events included oral mucositis, nausea, and fatigue; serious toxicities like pneumonitis were also reported. Frequent grade ≥3 events, often leading to dose modifications and discontinuation, mandate proactive mitigation strategies. Sac-TMT showed significant antitumor activity in recurrent endometrial cancer in the phase II KL264-01 study (ORR 34%, median PFS 6 months).44 The safety profile was primarily characterized by manageable hematologic toxicities (anemia, neutropenia) albeit with frequent, low-grade gastrointestinal events. Pivotal phase III studies, MK-2870-055 (NCT06132958) and ASCENT-GYN-01 (NCT06486441) are evaluating Sac-TMT and SG respectively, both against physician's choice of chemotherapy in patients who have progressed to platinum-based agents and immunotherapy. Furthermore, a maintenance strategy in pMMR tumors with Sac-TMT in combination with pembrolizumab is being explored (NCT06952504). Should these pivotal studies prove successful, they would represent a major therapeutic advance for patients with advanced endometrial cancer. HER2-targeted ADCs Although traditionally associated with breast and gastric cancers, HER2 overexpression is a feature in a distinct subset of endometrial cancer, mostly in cases with TP53 abnormalities and serous histology.88 Similar to ovarian cancer, standardisation of HER2 expression assessment in endometrial cancer is lacking. The DESTINY-PanTumor02 basket trial of T-DXd in HER2-expressing tumors included an endometrial cancer cohort of 40 patients (ORR 57.5%, median PFS 11 months).39 It is worth noting that across all subgroups, the highest ORR and longest median PFS were obtained in patients with high (3+) HER2 expression (84.6% and 11.9 months, respectively). Tolerability was consistent with its known safety profile, with an observed incidence of 10.5% of interstitial lung disease (ILD)/pneumonitis, mostly low grade. Following these positive results, the ongoing DESTINY-Endometrial01 (NCT06989112) is a phase III trial comparing first-line T-DXd (combined with either rilvegostomig or pembrolizumab) against standard-of-care chemo-immunotherapy in patients with MMR proficient, advanced or recurrent endometrial carcinoma. Trastuzumab pamirtecan (DB-1303/BNT323), which was designed for enhanced membrane permeability to allow for an improved bystander effect, yielded compelling preliminary results in a cohort of recurrent endometrial cancer (ORR 58%).84 Notably, the trial also included patients with lower HER2 expression levels. The most frequent treatment-emergent adverse events were nausea and fatigue. A phase III study (NCT06340568) is evaluating DB-1303/BNT323 in the second line setting against investigator's choice of chemotherapy and enrols patients with lower HER2 expression levels. FRα-targeted ADCs FRα expression is broadly distributed across several endometrial cancer histologies, thus making it a promising target for a wide population of patients. Analogous to ovarian cancer, MIRV is being evaluated in the advanced endometrial cancer setting. A phase I dose escalation trial included patients with serous and endometrioid endometrial cancer without prior determination of FRα, with MIRV showing preliminary signs of clinical efficacy.89 Monotherapy with MIRV is being evaluated further in an ongoing phase II trial (NCT03832361). Given the promising efficacy of MIRV and the growing role of immunotherapy in advanced endometrial cancer, combination strategies represent the next rational step. The combination of MIRV and pembrolizumab demonstrated promising clinical activity in a phase II trial in 16 patients with heavily pre-treated, FRα-positive, microsatellite stable (MSS) high grade serous endometrial cancer (ORR 37.5%).80 Some responses were highly durable, including one complete response lasting over 18 months, uncorrelated to FRα expression. Safety was consistent with the known adverse events profile of each agent. Rina-S is an additional FRα-targeting compound which differs from tubulin-directed therapies by its topoisomerase I inhibitor exatecan payload. The Phase I/II GCT1184-01 study evaluated this agent in 64 patients with metastatic or unresectable endometrial cancer previously treated with platinum-based chemotherapy and PD-L1 inhibitors. Rina-S showed an unconfirmed ORR of 50% and 45% in the 100 and 120 mg/m2 cohort respectively. This ADC was characterized by an absence of ocular complications, neuropathy, or ILD. Its toxicity profile was represented by low-grade gastrointestinal events (nausea, vomiting) and grade 3–4 myelosuppression.90 A phase III trial (RAINFOL-03–NCT07166094) is currently evaluating Rina-S against treatment of physician's choice (paclitaxel or doxorubicin) in recurrent or progressive EC. B7–H4-targeted ADCs B7–H4 represents an interesting target in endometrial cancer due to its relevant role in regulating T-cell activation and proliferation. Puxitatug samrotecan (AZD8205) targets B7–H4 using a novel, membrane-permeable topoisomerase 1 inhibitor. In a phase I/IIa dose-escalation study in patients with recurrent solid tumors, preliminary evidence of antitumor activity was observed (ORR 23% and 42% accross the 2.0 mg/kg and 2.4 mg/kg cohorts, respectively).50 Neutropenia, anemia and leukopenia were the most common grade ≥3 TRAE. Nausea was frequent, albeit primarily low-grade. Despite the frequency of these events, they did not result in treatment discontinuation for any patient, indicating that its toxicity profile was tolerable. These results have prompted an ongoing phase III trial in second line treatment comparing Puxitatug samrotecan against standard of care chemotherapy (NCT07044336). Other ADCs (XMT-1660 and GSK5733584/HS20089) are currently in early stages of clinical development.53,91 ADCs in cervical cancer Cervical cancer is the fourth most common cancer both in terms of incidence and cancer mortality among females globally.1 Current first line therapy for advanced disease includes chemotherapy and immunotherapy with or without bevacizumab.92 Novel therapeutic strategies are urgently needed as the five year OS is only ∼17% for patients with metastatic disease.93 Similar to the aforementioned cancers, ADCs targeting TROP2 and HER2 are also under investigation in cervical cancer. Additional ADC targets of interest in cervical cancer include Nectin-4 and B7–H3 (Table 396,97 and Figure S1).Table 3Efficacy and safety of selected ADCs in cervical cancer.aWhen available.ADC, antibody drug conjugation; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TF, Tissue Factor; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2.According to ClinicalTrials.gov (accessed on 27 November 2025). Table 3Efficacy and safety of selected ADCs in cervical cancer.aWhen available.ADC, antibody drug conjugation; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TF, Tissue Factor; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2.According to ClinicalTrials.gov (accessed on 27 November 2025). Efficacy and safety of selected ADCs in cervical cancer. aWhen available. ADC, antibody drug conjugation; AEs, adverse events; DCR, disease control rate; FRα, Folate Receptor alpha; HER2, Human Epidermal Growth Factor Receptor 2; NA, not available; ORR, objective response rate; TEAEs, treatment-emergent adverse events; TF, Tissue Factor; TRAEs, treatment-related adverse events; TROP2, Trophoblast Cell Surface Antigen 2. According to ClinicalTrials.gov (accessed on 27 November 2025). Tissue factor-targeted ADCs Tissue factor acts as a negative prognostic indicator in cervical carcinoma, as its overexpression correlates with advanced FIGO stage, lymph node metastasis, and poor overall survival.28 This antigen is the specific target for the antibody–drug conjugate Tisotumab vedotin (TV). The pivotal phase III study innovaTV 301, which compared TV to the investigator's choice of chemotherapy in the relapsed cervical cancer setting, showed that TV significantly reduced the risk of relapse and death compared to chemotherapy (median PFS 4.2 vs 2.9 months, HR 0.67; median OS 11.5 vs 9.5 months, HR 0.70; ORR 17.8% vs 5.2%).94 These findings resulted in TV being established as a new standard of care for cervical cancer after progression to first line systemic therapy, and subsequently sparked interest in exploring TV's potential synergy with other agents. Thus, the phase Ib/II innovaTV 205 trial investigated combinations of TV with either bevacizumab, carboplatin or pembrolizumab, in both first line and relapsed settings.95 A recent 5-year update showed significant outcomes with TV combined with carboplatin in the first-line setting (ORR 54.5%, mPFS 6.9 months, mOS 25.5 months).103 The pembrolizumab doublet in the first-line setting showed encouraging long-term survival outcomes (ORR 40.6%, mPFS 5.3 months, mOS 30.7 months), whereas in later lines it demonstrated activity consistent with the relapsed setting (ORR 35.3%, mPFS 5.6 months, mOS 15.3 months). Notably, the safety profile of these combinations was generally well-tolerated, with infrequent discontinuations due to side effects. The results of the arm assessing the first line combination of TV, carboplatin, pembrolizumab ± bevacizumab are also awaited. TROP2-targeted ADCs TROP2 is overexpressed in the majority of cervical cancer and is an independent predictor of poor prognosis, with high expression correlated with decreased OS.99,104 An interim analysis of the phase II basket study EVER-132-003 evaluating SG in 40 asian patients with advanced pre-treated cervical cancer (some having received prior immunotherapy) showed promising anti-tumor efficacy (ORR 43%; median PFS 7.1 months; median OS 16.5 months). However, grade ≥3 events were present in 63% of patients, and 3 patients discontinued treatment due to toxicities.98 Concurrently, Sac-TMT is advancing through late-stage clinical development. This progress is based on the phase I/II study KL264-01, an open-label, multi-cohort basket trial evaluating Sac-TMT in patients with locally advanced or metastatic solid tumors refractory to standard therapies. In the cervical cancer cohort, Sac-TMT demonstrated encouraging antitumor activity with a confirmed ORR of 24% and a median PFS of 5.5 months. Treatment with Sac-TMT was associated with significant hematological toxicities, with grade ≥3 TRAEs occurring in 53% of patients, chiefly anemia (26%) and neutropenia (16%). Nevertheless, there was a low treatment discontinuation rate of 2%, indicating that these adverse events were rarely treatment-limiting.105 Furthermore, emerging evidence regarding the interplay between TROP2 and immune exclusion in solid tumors raises the possibility of a synergistic effect with checkpoint inhibitors.106,107 In line with this hypothesis, an expansion cohort of the aforementioned KL264-01 study is evaluating the combination of Sac-TMT with pembrolizumab (38 patients; 47% with two prior lines of therapy, 53% pre-treated with bevacizumab, 42% pre-treated with anti-PD-1). Interim results report an ORR of 57.9% (including 3 complete responses) regardless of prior immunotherapy exposure.100 Responses were durable, with a 6-month DoR rate of over 80%. Given these encouraging results in the relapsed setting, a Phase III trial (NCT07216703) is now evaluating this combination in the first-line setting. Following standard modern platinum-based induction (including pembrolizumab with or without bevacizumab), this study is assessing the addition of Sac-TMT to the standard maintenance backbone. Other ADCs HER2-targeted ADC HER2 overexpression is present in approximately 5% of cervical cancer cases.108 Among patients with HER2 2+ or 3+ recurrent cervical cancer treated with T-Dxd in DESTINY-PanTumor02, a remarkable 50% ORR and a median PFS of 7 months was achieved.39 In concordance with other enrolled cohorts, a trend toward superior responses in patients with the highest HER2 expression was observed. Nectin-4-targeted ADC Bulumtatug fuvedotin (9MW281) showed promising outcomes in a phase I study of 53 patients with relapsed cervical carcinoma (ORR 32%, median PFS 3.9 months). The most prevalent side effects were hematological (anemia, neutropenia), increased liver transaminases and rash.101 ADRX-0706 showed anti-tumor activity with manageable toxicities, according to the preliminary results of a phase I basket trial which included cervical cancer patients who had at least one prior line of systemic.102 B7–H3-targeted ADC In a phase I/IIa trial, DB-1311/BNT324 showed encouraging signs of efficacy in patients with advanced solid tumors.109 Within a small cohort of 7 relapsed cervical cancer patients, three achieved a complete response, demonstrating B7–H3 as a promising target for this malignancy and warranting further investigation. Early clinical experience with ADCs in endometrial and cervical cancers indicates encouraging activity across several targets, accompanied by distinct safety profiles. However, the majority of available efficacy data comes from early phase trials with limited follow-up and heterogenous population, underscoring the need for confirmatory results from phase 3 trials. Safety of ADCs and multidisciplinary management Although ADCs were designed with the rationale of expanding the therapeutic index of conventional chemotherapy, the toxicity profile of any given ADC is a reflection of its antibody, linker, and cytotoxic payload components. While class-wide toxicities such as myelosuppression and fatigue are frequent, certain adverse events of special interest (AESI) warrant particular attention. Effective management of these AESIs is paramount to minimizing treatment interruptions and requires a proactive, multidisciplinary approach (Table 4).Table 4Summary of toxicity management of adverse events of special interest.ToxicityDrugPreventionManagementOcularMirvetuximab soravtansine•Ophthalmic examination at baseline and every 2 cycles up to 8th and as needed•Daily use of lubricating eye drops at least ×4/daily and as neededRefrain from wearing contact lenses.Use a UVA/UVB blocking sunglasses while on treatmentKeratitisNon confluent superficial punctate conjunctival defects, mild vasodilatationMonitorConfluent superficial, corneal epithelial defect, 3-line or more loss in corrected visual acuityHold dose until improvement, resume at same dose. Dose reduction if recurrent confluent despite best care or ocular toxicity lasting longer than 14 daysCorneal ulcer or stromal opacity or best corrected distance visual acuity 6/60 or worseHold dose until improvement or resolution, then reduce MIRV by one dose levelCorneal perforationPermanently discontinueTisotumab vedotin•Ophthalmic examination at baseline and prior to each cycle•Daily use of lubricating eye drops at least 4 times daily and for 30 days after the last infusion•Corticosteroid eye dropsa: 1 drop each eye ×3/daily 10 min before drug infusion, on D1-D3 (during 72 h after)•Vasoconstrictor eye dropsb: 3 drops on each eye immediately before each tisotumab vedotin (TV) infusion and as needed•Eye cooling pads during TV infusion: for 60 min, start prior each infusion and continue for other 20 min after infusion complete.ConjunctivitisNonconfluent superficial punctate conjunctival defects, mild vasodilatationConsider administering topical steroid drops frequently. Monitor.Confluent superficial punctate conjunctival defects, moderate to severe vasodilatationConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).First occurrence: withhold until resolution or improvement to nonconfluent, then resume at same dose level.Second occurrence: same as first but resume −1 dose level. If no resolution or improvement, permanently discontinue.Third occurrence: permanently discontinue.Conjunctival ulceration, neovascularization, or fibrovascular scarringConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour). Permanently discontinueAny scarring or symblepharonPermanently discontinueKeratitisNonconfluent superficial keratitisConsider administering topical steroid drops frequently. MonitorConfluent superficial keratitis, a corneal epithelial defect, or a 3 line or more loss in best corrected visual acuityConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).First recurrence: withhold until improvement to nonconfluent, then resume −1 dose level. Second recurrence: permanently discontinueUlcerative keratitis or perforationConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).Permanently discontinueILDTrastuzumab deruxtecan•History and physical examination, vital signs•Baseline chest high-resolution CT scan•Pulmonary function testing•Baseline SpO2•Provide patient education on risk and symptom identificationConsider pulmonary consult for patients with significant lung comorbiditiesOn treatment•Plan serial chest HRCT (e.g., every 6–9 weeks or every 2–3 cycles)•Symptom checks at each infusionSuspected ILD•Hold drug•Perform HRCT•Laboratory work-up•Infectious evaluation (PJP/viral)Pulmonary consultationG1—Asymptomatic with clinical or diagnostic (e.g., radiological) findings only:•Hold drug•Closely follow up in 2–7 d for onset of symptoms and monitor patient until radiological resolution•Consider CT imaging in 1–2 weeks or as clinically indicated•May consider starting systemic prednisolone (0.5 mg/kg/day) until improvement followed by taper over at least 4 weeksa•Drug can be resumed if ILD resolves to G0:-If resolved ≤28 days maintain same dose-If resolved ≥28 days reduce −1 level doseDiscontinue if it occurs beyond day 22 and has not resolved within 49 days from the last infusionIf worsening of diagnostic observations despite initiation of corticosteroids, follow indications for G ≥ 2 pneumonitis (if the patient is asymptomatic, then they should still be considered as G1, even if corticosteroid treatment is given)G2—Symptomatic; instrumental ADLs are limited, and medical intervention indicated:•Permanently discontinue•Start systemic prednisolone (≥1 mg/kg/day) for 14 or more until complete resolution of clinical and CT, followed by taper over at least 4 weeks•Monitor patient every 3–5 days, serial imaging at least every 1–2 weeks and spirometry, afterward as clinically indicated until resolutionIf no improvement or the clinical or diagnostic findings worsen within 5 days, consider escalating the corticosteroid dose and/or switching to IV administrationReassess for other possible causesConsider Pneumocystis antimicrobial prophylaxisG3—Severe symptoms; self-care ADLs are limited, and oxygen is indicated:•Permanently discontinue•Hospitalization is required•Start methylprednisolone i.v. (e.g., 500–1000 mg/day for 3 d, followed by ≥ 1 mg/kg/day prednisolone for 14 d or more or until both clinical symptoms and CT abnormalities resolve, followed by a gradual taper over at least 4 weeks•Repeat imaging at least every 1–2 weeks afterwards as clinically appropriate•If no improvement after 3–5 days, consider other immunosuppressive agents (e.g., infliximab or mycophenolate mofetil)If no improvement within 3–5 days reassesses for other possible etiologiesConsider Pneumocystis antimicrobial prophylaxisMucositisStomatitisSacituzumab govitecanDatopotamab deruxtecanSacituzumab tirumotecan•Assess for risk factors: smoking, nutritional status, etc, spicy/acidic foods, alcohol, tobacco•Educate patients on meticulous and frequent oral hygiene and consider pre-treatment dental assessment•Implement routine self-monitoring and immediate reporting of oral symptoms•Use daily gentle brushing with a soft-bristle toothbrush and regular flossing•Utilize mucoadhesive gels or calcium phosphate rinses for a protective oral coating•Utilize steroid mouthwash (4 times a day, swish for 1–2 min each time) especially for high-risk ADCs (Dato-Dxd, Sac-TMT)•Ensure adequate hydration and plan for protein foods•Consider oral cryotherapy (ice chips) during infusion•Apply a hydrating lip balm regularly to prevent dry lipsSacituzumab govitecanG1: Continue treatmentG2: Hold until ≤ Grade 1, then reduce dose by 25%G3: Hold until ≤ Grade 1, then reduce dose by 50%G4: Hold until ≤ Grade 1, then reduce dose by 50%. Consider discontinuationDatopotamab deruxtecanG1: Maintain dose. Optimize supportive careG2: Consider a dose delay/reduction. Optimize supportive careG3: Hold until ≤ Grade 1. Then:If prophylaxis wasn't optimized: Resume at same doseIf prophylaxis was optimized: Reduce dose by one levelG4: Permanently discontinueSacituzumab tirumotecanG1: Maintain dose. Optimize supportive careG2: Hold until ≤ Grade 1, then resume at same dose. For recurrent G2, consider a dose reductionG3: Hold until ≤ Grade 1, then reduce dose by one levelG4: Permanently discontinueBleedingTisotumab vedotin•Assessment of hemorrhagic risk factors•Clinical and laboratory monitoring•Patient education to promptly report any bleeding episode, even if mild•Caution with anticoagulants or invasive proceduresAny grade pulmonary or CNS (any occurrence): permanently discontinueG2 in any other site: withhold until resolved, then resume treatment at the same doseG3 in any other site:-First occurrence: withhold until resolved, then resume treatment at the same dose-Second occurrence: permanently discontinueG4 in any other site: permanently discontinueOcular toxicity was graded according to the terminology reported in the Summary of Product Characteristics of Tisotumab Vedotin and Mirvetuximab soravtansine.Other toxicities were graded per National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0).aEg. Prednisolone acetate opthalmic suspension 1% or dexamethasone 0.1% or its equivalent.bEg. Brimonidine tartrate 0.2% or Tetryzoline 0.05% or its equivalent. Table 4Summary of toxicity management of adverse events of special interest.ToxicityDrugPreventionManagementOcularMirvetuximab soravtansine•Ophthalmic examination at baseline and every 2 cycles up to 8th and as needed•Daily use of lubricating eye drops at least ×4/daily and as neededRefrain from wearing contact lenses.Use a UVA/UVB blocking sunglasses while on treatmentKeratitisNon confluent superficial punctate conjunctival defects, mild vasodilatationMonitorConfluent superficial, corneal epithelial defect, 3-line or more loss in corrected visual acuityHold dose until improvement, resume at same dose. Dose reduction if recurrent confluent despite best care or ocular toxicity lasting longer than 14 daysCorneal ulcer or stromal opacity or best corrected distance visual acuity 6/60 or worseHold dose until improvement or resolution, then reduce MIRV by one dose levelCorneal perforationPermanently discontinueTisotumab vedotin•Ophthalmic examination at baseline and prior to each cycle•Daily use of lubricating eye drops at least 4 times daily and for 30 days after the last infusion•Corticosteroid eye dropsa: 1 drop each eye ×3/daily 10 min before drug infusion, on D1-D3 (during 72 h after)•Vasoconstrictor eye dropsb: 3 drops on each eye immediately before each tisotumab vedotin (TV) infusion and as needed•Eye cooling pads during TV infusion: for 60 min, start prior each infusion and continue for other 20 min after infusion complete.ConjunctivitisNonconfluent superficial punctate conjunctival defects, mild vasodilatationConsider administering topical steroid drops frequently. Monitor.Confluent superficial punctate conjunctival defects, moderate to severe vasodilatationConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).First occurrence: withhold until resolution or improvement to nonconfluent, then resume at same dose level.Second occurrence: same as first but resume −1 dose level. If no resolution or improvement, permanently discontinue.Third occurrence: permanently discontinue.Conjunctival ulceration, neovascularization, or fibrovascular scarringConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour). Permanently discontinueAny scarring or symblepharonPermanently discontinueKeratitisNonconfluent superficial keratitisConsider administering topical steroid drops frequently. MonitorConfluent superficial keratitis, a corneal epithelial defect, or a 3 line or more loss in best corrected visual acuityConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).First recurrence: withhold until improvement to nonconfluent, then resume −1 dose level. Second recurrence: permanently discontinueUlcerative keratitis or perforationConsider administering topical steroid drops in combination with antibiotics prophylaxis frequently (every second hour).Permanently discontinueILDTrastuzumab deruxtecan•History and physical examination, vital signs•Baseline chest high-resolution CT scan•Pulmonary function testing•Baseline SpO2•Provide patient education on risk and symptom identificationConsider pulmonary consult for patients with significant lung comorbiditiesOn treatment•Plan serial chest HRCT (e.g., every 6–9 weeks or every 2–3 cycles)•Symptom checks at each infusionSuspected ILD•Hold drug•Perform HRCT•Laboratory work-up•Infectious evaluation (PJP/viral)Pulmonary consultationG1—Asymptomatic with clinical or diagnostic (e.g., radiological) findings only:•Hold drug•Closely follow up in 2–7 d for onset of symptoms and monitor patient until radiological resolution•Consider CT imaging in 1–2 weeks or as clinically indicated•May consider starting systemic prednisolone (0.5 mg/kg/day) until improvement followed by taper over at least 4 weeksa•Drug can be resumed if ILD resolves to G0:-If resolved ≤28 days maintain same dose-If resolved ≥28 days reduce −1 level doseDiscontinue if it occurs beyond day 22 and has not resolved within 49 days from the last infusionIf worsening of diagnostic observations despite initiation of corticosteroids, follow indications for G ≥ 2 pneumonitis (if the patient is asymptomatic, then they should still be considered as G1, even if corticosteroid treatment is given)G2—Symptomatic; instrumental ADLs are limited, and medical intervention indicated:•Permanently discontinue•Start systemic prednisolone (≥1 mg/kg/day) for 14 or more until complete resolution of clinical and CT, followed by taper over at least 4 weeks•Monitor patient every 3–5 days, serial imaging at least every 1–2 weeks and spirometry, afterward as clinically indicated until resolutionIf no improvement or the clinical or diagnostic findings worsen within 5 days, consider escalating the corticosteroid dose and/or switching to IV administrationReassess for other possible causesConsider Pneumocystis antimicrobial prophylaxisG3—Severe symptoms; self-care ADLs are limited, and oxygen is indicated:•Permanently discontinue•Hospitalization is required•Start methylprednisolone i.v. (e.g., 500–1000 mg/day for 3 d, followed by ≥ 1 mg/kg/day prednisolone for 14 d or more or until both clinical symptoms and CT abnormalities resolve, followed by a gradual taper over at least 4 weeks•Repeat imaging at least every 1–2 weeks afterwards as clinically appropriate•If no improvement after 3–5 days, consider other immunosuppressive agents (e.g., infliximab or mycophenolate mofetil)If no improvement within 3–5 days reassesses for other possible etiologiesConsider Pneumocystis antimicrobial prophylaxisMucositisStomatitisSacituzumab govitecanDatopotamab deruxtecanSacituzumab tirumotecan•Assess for risk factors: smoking, nutritional status, etc, spicy/acidic foods, alcohol, tobacco•Educate patients on meticulous and frequent oral hygiene and consider pre-treatment dental assessment•Implement routine self-monitoring and immediate reporting of oral symptoms•Use daily gentle brushing with a soft-bristle toothbrush and regular flossing•Utilize mucoadhesive gels or calcium phosphate rinses for a protective oral coating•Utilize steroid mouthwash (4 times a day, swish for 1–2 min each time) especially for high-risk ADCs (Dato-Dxd, Sac-TMT)•Ensure adequate hydration and plan for protein foods•Consider oral cryotherapy (ice chips) during infusion•Apply a hydrating lip balm regularly to prevent dry lipsSacituzumab govitecanG1: Continue treatmentG2: Hold until ≤ Grade 1, then reduce dose by 25%G3: Hold until ≤ Grade 1, then reduce dose by 50%G4: Hold until ≤ Grade 1, then reduce dose by 50%. Consider discontinuationDatopotamab deruxtecanG1: Maintain dose. Optimize supportive careG2: Consider a dose delay/reduction. Optimize supportive careG3: Hold until ≤ Grade 1. Then:If prophylaxis wasn't optimized: Resume at same doseIf prophylaxis was optimized: Reduce dose by one levelG4: Permanently discontinueSacituzumab tirumotecanG1: Maintain dose. Optimize supportive careG2: Hold until ≤ Grade 1, then resume at same dose. For recurrent G2, consider a dose reductionG3: Hold until ≤ Grade 1, then reduce dose by one levelG4: Permanently discontinueBleedingTisotumab vedotin•Assessment of hemorrhagic risk factors•Clinical and laboratory monitoring•Patient education to promptly report any bleeding episode, even if mild•Caution with anticoagulants or invasive proceduresAny grade pulmonary or CNS (any occurrence): permanently discontinueG2 in any other site: withhold until resolved, then resume treatment at the same doseG3 in any other site:-First occurrence: withhold until resolved, then resume treatment at the same dose-Second occurrence: permanently discontinueG4 in any other site: permanently discontinueOcular toxicity was graded according to the terminology reported in the Summary of Product Characteristics of Tisotumab Vedotin and Mirvetuximab soravtansine.Other toxicities were graded per National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0).aEg. Prednisolone acetate opthalmic suspension 1% or dexamethasone 0.1% or its equivalent.bEg. Brimonidine tartrate 0.2% or Tetryzoline 0.05% or its equivalent. Summary of toxicity management of adverse events of special interest. •Ophthalmic examination at baseline and every 2 cycles up to 8th and as needed Ophthalmic examination at baseline and every 2 cycles up to 8th and as needed •Daily use of lubricating eye drops at least ×4/daily and as needed Daily use of lubricating eye drops at least ×4/daily and as needed •Ophthalmic examination at baseline and prior to each cycle Ophthalmic examination at baseline and prior to each cycle •Daily use of lubricating eye drops at least 4 times daily and for 30 days after the last infusion Daily use of lubricating eye drops at least 4 times daily and for 30 days after the last infusion •Corticosteroid eye dropsa: 1 drop each eye ×3/daily 10 min before drug infusion, on D1-D3 (during 72 h after) Corticosteroid eye dropsa: 1 drop each eye ×3/daily 10 min before drug infusion, on D1-D3 (during 72 h after) •Vasoconstrictor eye dropsb: 3 drops on each eye immediately before each tisotumab vedotin (TV) infusion and as needed Vasoconstrictor eye dropsb: 3 drops on each eye immediately before each tisotumab vedotin (TV) infusion and as needed •Eye cooling pads during TV infusion: for 60 min, start prior each infusion and continue for other 20 min after infusion complete. Eye cooling pads during TV infusion: for 60 min, start prior each infusion and continue for other 20 min after infusion complete. •History and physical examination, vital signs History and physical examination, vital signs •Baseline chest high-resolution CT scan Baseline chest high-resolution CT scan •Pulmonary function testing Pulmonary function testing •Baseline SpO2 Baseline SpO2 •Provide patient education on risk and symptom identification Provide patient education on risk and symptom identification •Plan serial chest HRCT (e.g., every 6–9 weeks or every 2–3 cycles) Plan serial chest HRCT (e.g., every 6–9 weeks or every 2–3 cycles) •Symptom checks at each infusion Symptom checks at each infusion •Hold drug Hold drug •Perform HRCT Perform HRCT •Laboratory work-up Laboratory work-up •Infectious evaluation (PJP/viral) Infectious evaluation (PJP/viral) •Hold drug Hold drug •Closely follow up in 2–7 d for onset of symptoms and monitor patient until radiological resolution Closely follow up in 2–7 d for onset of symptoms and monitor patient until radiological resolution •Consider CT imaging in 1–2 weeks or as clinically indicated Consider CT imaging in 1–2 weeks or as clinically indicated •May consider starting systemic prednisolone (0.5 mg/kg/day) until improvement followed by taper over at least 4 weeksa May consider starting systemic prednisolone (0.5 mg/kg/day) until improvement followed by taper over at least 4 weeksa •Drug can be resumed if ILD resolves to G0:-If resolved ≤28 days maintain same dose-If resolved ≥28 days reduce −1 level dose Drug can be resumed if ILD resolves to G0:-If resolved ≤28 days maintain same dose-If resolved ≥28 days reduce −1 level dose -If resolved ≤28 days maintain same dose If resolved ≤28 days maintain same dose -If resolved ≥28 days reduce −1 level dose If resolved ≥28 days reduce −1 level dose •Permanently discontinue Permanently discontinue •Start systemic prednisolone (≥1 mg/kg/day) for 14 or more until complete resolution of clinical and CT, followed by taper over at least 4 weeks Start systemic prednisolone (≥1 mg/kg/day) for 14 or more until complete resolution of clinical and CT, followed by taper over at least 4 weeks •Monitor patient every 3–5 days, serial imaging at least every 1–2 weeks and spirometry, afterward as clinically indicated until resolution Monitor patient every 3–5 days, serial imaging at least every 1–2 weeks and spirometry, afterward as clinically indicated until resolution •Permanently discontinue Permanently discontinue •Hospitalization is required Hospitalization is required •Start methylprednisolone i.v. (e.g., 500–1000 mg/day for 3 d, followed by ≥ 1 mg/kg/day prednisolone for 14 d or more or until both clinical symptoms and CT abnormalities resolve, followed by a gradual taper over at least 4 weeks Start methylprednisolone i.v. (e.g., 500–1000 mg/day for 3 d, followed by ≥ 1 mg/kg/day prednisolone for 14 d or more or until both clinical symptoms and CT abnormalities resolve, followed by a gradual taper over at least 4 weeks •Repeat imaging at least every 1–2 weeks afterwards as clinically appropriate Repeat imaging at least every 1–2 weeks afterwards as clinically appropriate •If no improvement after 3–5 days, consider other immunosuppressive agents (e.g., infliximab or mycophenolate mofetil) If no improvement after 3–5 days, consider other immunosuppressive agents (e.g., infliximab or mycophenolate mofetil) •Assess for risk factors: smoking, nutritional status, etc, spicy/acidic foods, alcohol, tobacco Assess for risk factors: smoking, nutritional status, etc, spicy/acidic foods, alcohol, tobacco •Educate patients on meticulous and frequent oral hygiene and consider pre-treatment dental assessment Educate patients on meticulous and frequent oral hygiene and consider pre-treatment dental assessment •Implement routine self-monitoring and immediate reporting of oral symptoms Implement routine self-monitoring and immediate reporting of oral symptoms •Use daily gentle brushing with a soft-bristle toothbrush and regular flossing Use daily gentle brushing with a soft-bristle toothbrush and regular flossing •Utilize mucoadhesive gels or calcium phosphate rinses for a protective oral coating Utilize mucoadhesive gels or calcium phosphate rinses for a protective oral coating •Utilize steroid mouthwash (4 times a day, swish for 1–2 min each time) especially for high-risk ADCs (Dato-Dxd, Sac-TMT) Utilize steroid mouthwash (4 times a day, swish for 1–2 min each time) especially for high-risk ADCs (Dato-Dxd, Sac-TMT) •Ensure adequate hydration and plan for protein foods Ensure adequate hydration and plan for protein foods •Consider oral cryotherapy (ice chips) during infusion Consider oral cryotherapy (ice chips) during infusion •Apply a hydrating lip balm regularly to prevent dry lips Apply a hydrating lip balm regularly to prevent dry lips •Assessment of hemorrhagic risk factors Assessment of hemorrhagic risk factors •Clinical and laboratory monitoring Clinical and laboratory monitoring •Patient education to promptly report any bleeding episode, even if mild Patient education to promptly report any bleeding episode, even if mild •Caution with anticoagulants or invasive procedures Caution with anticoagulants or invasive procedures -First occurrence: withhold until resolved, then resume treatment at the same dose First occurrence: withhold until resolved, then resume treatment at the same dose -Second occurrence: permanently discontinue Second occurrence: permanently discontinue Ocular toxicity was graded according to the terminology reported in the Summary of Product Characteristics of Tisotumab Vedotin and Mirvetuximab soravtansine. Other toxicities were graded per National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0). Eg. Prednisolone acetate opthalmic suspension 1% or dexamethasone 0.1% or its equivalent. Eg. Brimonidine tartrate 0.2% or Tetryzoline 0.05% or its equivalent. Ocular surface events are the main toxicities for both TV and MIRV, but the mechanism of ocular toxicity differs for these two ADCs, thus dictating their distinct management strategies.110 The target-antigen for TV is expressed on corneal epithelial cells, resulting in TV binding directly to the corneal epithelium and delivering its cytotoxic MMAE payload. In contrast, the target for MIRV (FRα) is absent in the cornea. The cytoxicity from MIRV is instead believed to be an off-target effect from non-specific uptake of the ADC or its DM4 payload by corneal cells. The management of TV-associated ocular toxiciy requires a mandatory prophylactic regimen which includes pre-infusion vasoconstrictor and corticosteroid eye drops, cooling eye packs during infusion, and consistent use of lubricating drops. Conversely, management for MIRV-associated ocular toxicity is multifaceted. The strategy involves supportive care with prophylactic lubricating eye drops, avoidance of contact lenses, and vigilant ophthalmological monitoring. In addition to these local therapies, toxicity can be managed through dose interruption and/or reductions. Discrepancies in management are mainly in the corticosteroid eye drops: the FDA endorses proactive use, whereas the EMA advises a reactive approach (only upon grade ≥2 toxicity) to mitigate risks of long-term steroid use. Ocular toxicity is also a significant consideration for Dato-DXd, as TROP2 is constitutively expressed in the corneal and conjunctival tissues. In the TROPION-Breast02 study, treatment-related ocular surface events were reported in 47% of patients, manifesting primarily as dry eye, conjunctivitis, and keratitis.111 Despite its high incidence, toxicities were largely manageable and low-grade. In contrast, SG is not associated with significant corneal toxicity. Although both ADCs share the same target, this discordance is likely attributable to differences in linker stability and payload pharmacokinetics. By targeting tissue factor, TV disrupts the coagulation cascade, causing treatment-related bleeding such as epistaxis (30%), vaginal hemorrhage (7%), and hematuria (3%). Management entails withholding ADC dosing until resolution for Grade 2 events (moderate, in which medical intervention is required) or initial Grade 3 events (severe, mandating either transfusional support or surgical intervention). Permanent discontinuation is mandated for any occurrence of pulmonary or central nervous system hemorrhage. Interstitial lung disease (ILD)/pneumonitis represents a serious and potentially fatal toxicity associated with ADCs. Current evidence indicates that this adverse event is triggered by alveolar macrophages non-specifically internalizing the ADC via Fc receptors, resulting in cytotoxic release and lung inflammation. Therefore, this risk transcends specific targets and payloads. While T-DXd serves as the archetype of this toxicity, it has also been reported with Dato- DXd, DB-1303/BNT323 and MIRV. Vigilant monitoring for any new or worsening respiratory symptoms, alongside routine imaging, is critical for early detection. Management follows the “Five S's”112: Screen (careful patient selection and regular clinical assessments), Scan frequently (radiological scans, preferably high-resolution CT, every 6–12 weeks), Synergy (patient education and multidisciplinary management), Suspend treatment (interruption of the ADC if ILD is suspected), and administer Steroids (prompt intervention with high-dose corticosteroids for any suspected or confirmed cases of grade ≥2 ILD, for which the ADC must be permanently discontinued). Finally, oral mucositis and stomatitis are common and often debilitating side effects, particularly with topoisomerase I inhibitor payloads such as those in Dato-DXd, Sac-TMT and DB-1305/BNT325.113 These events can significantly impact quality of life and lead to dose interruptions. Prophylactic measures are therefore recommended, including meticulous oral hygiene, oral cryotherapy and the use of a steroid-containing mouthwash. For active events, management includes supportive care with topical anesthetics and analgesics, with dose modifications required for more severe cases. Given the broad and complex side effect profile of ADCs, a coordinated, multidisciplinary team is crucial for prompt recognition and specialized management. This collaborative effort must extend beyond medical specialists to include the patient and their caregivers, general practitioners and nurses, all of whom play a vital role in early symptom recognition. The implementation of this complex, multidisciplinary approach raises concerns regarding its feasibility in real-world clinical practice, particularly in non specialized centers and low-resource settings. Open questions and future directions The rapid expansion of the ADC armamentarium raises several important questions regarding their optimal use, from patient selection to treatment sequencing, mechanisms of resistance and combination strategies. Lessons learned from other tumor types, particularly breast cancer, can inform the future development and application of ADCs in gynaecological cancers. Need for predictive biomarkers A central issue is the identification of robust predictive biomarkers of ADC activity to guide patient selection. ADCs were conceived as a step forward towards precision medicine, yet their clinical activity often extends beyond a simple drug-to-target correlation. In the field of breast cancer for instance, the success of T-DXd in HER2-low and ultra-low tumors suggests that other factors modulate ADC effectiveness (e.g., payload sensitivity, tumor permeability, bystander effect).6,114 In gynaecological cancers, it has been observed that even among patients with high FRα expression, responses are variable, suggesting that antigen expression alone is insufficient to fully predict treatment benefit. This variability can be attributed to intra-tumoral heterogeneity, both spatial and temporal. Indeed, tumors comprise different cellular subpopulations which differ across anatomical sites and evolve during treatment.115 This heterogeneity limits the utility of static biomarker assessments (e.g., immunohistochemistry at diagnosis) and underscores the need for dynamic characterization strategies (e.g., serial biopsies, liquid biopsies, advanced imaging techniques).114,116 Moreover, the absence of standardized assays for cell surface targets across clinical trials has led to inconsistencies in patient eligibility criteria and variability in treatment responses. The clinical development of MIRV, for example, underscores the critical need for uniform and quantitative antigen detection methodologies to optimize patient selection and therapeutic efficacy. The optimal timing for biomarker testing to guide the use ADCs in gynecologic cancers depends on the biological stability of the biomarker and its modulation over the course of the disease and prior therapies. Biomarkers that demonstrate relative temporal stability and concordance between primary and recurrent disease, such as FRα could be reliably assessed using archival tumor tissue. In contrast, biomarkers characterized by spatial and temporal heterogeneity, or those that are dynamic and treatment-induced, such as HER2, may exhibit significant changes between primary tumors and recurrent or metastatic lesions. In these settings, testing on recent tumor tissue is preferable to accurately capture the current biomarker status and optimize ADC efficacy.13,117 Histological subtype further influences antigen expression, particularly in ovarian cancer, warranting stratification by histotype in trial design and therapeutic decisions.118 Research is now focused not only on refining methods of measuring antigen expression, but also on identifying genomic markers of payload sensitivity. For example, mutations in the toposiomerase 1 gene were reported to arise in vivo under selective pressure from ADCs, representing a biomarker of resistance to topoisomerase I inhibitor-based ADCs. As such, parallel efforts to refine both antigen-targeted and payload-related predictive biomarkers are critical for improving ADC efficacy.119 ADC sequencing With multiple ADCs entering the scene, the question of optimal sequencing is paramount. In breast cancer, the established efficacy of T-DXd after progression on T-DM1 demonstrates that switching the payload while targeting the same antigen can be a successful strategy. In contrast, sequencing two ADCs with different targets but with similar payload (e.g., T-DXd and SG, both with topoisomerase I inhibitor payload) may lead to diminished activity due to potential payload class cross-resistance.120,121 This consideration is particularly relevant for tumors expressing multiple targets, which represent a common clinical scenario where a wide range of therapeutic options are available. In breast cancer, studies also support sequencing T-DXd before SG in nearly all patients with advanced HER2-negative breast cancer.122 Overall, ideal sequencing strategies are yet to be prospectively defined, particularly in gynecologic malignancies, highlighting the need for further research in this field.123,124 ADC resistance Underlying the issue of sequencing is the complex biology of mechanisms of resistance.125 Target-related resistance arises from reduced or heterogeneous antigen expression, often induced by selective treatment pressure. In order to overcome target-related resistance, novel approaches (e.g., spatial tissue analysis, liquid biopsy, molecular imaging) aim to capture and monitor biomarkers evolving over time during tumor treatment or progression.114,116,126 Resistance to the payload itself can occur through the upregulation of drug efflux pumps (e.g., P-glycoprotein), mutations in the payload target (e.g., tubulin, TOP1), and activation of DNA repair pathways in response to DNA-damaging agents.127 Additionally, dysregulation in ADC internalization, or lysosomal trafficking or processing may impair release of the payload.128 Combination therapies and treatment setting The most promising strategy to overcome resistance to ADC lies in combination treatment strategies. Several rational combinations are under active investigation in gynaecological malignancies: pairing ADCs with immune checkpoint inhibitors, antiangiogenic agents, traditional chemotherapies, or targeted therapies like PARP inhibitors.129 Preclinical and early-phase clinical trials have shown that such combinations could lead to synergistic anti-cancer effects compared to monotherapy.95,130 There is a strong rationale for combining ADCs with immune checkpoint inhibitors. The cancer cells killed by ADCs could release tumor neoantigens and prime the tumor microenvironment for immune engagement. Early trials combining ADCs with pembrolizumab showed encouraging results, with manageable safety profile, even among cervical cancer patients who were pre-treated with anti-PD-1.100,131 Combinations with antiangiogenic agents like bevacizumab are also being tested, with the hypothesis that normalizing tumor vasculature could improve ADC delivery and reduce hypoxia-driven resistance. For example, the phase III DESTINY Ovarian 01 (NCT06819007) will evaluate the safety and efficacy of T-DXd in combination with bevacizumab vs bevacizumab monotherapy as first line maintenance in newly diagnosed advanced high-grade HER2-expressing ovarian cancer.132 The sequential or concurrent administration of ADCs alongside conventional chemotherapeutic agents may enhance tumor cell killing.95 Nevertheless, such combinations require careful management due to the potential for overlapping toxicities, particularly myelosuppression. Other ongoing clinical trials are investigating the potential of switching to ADC maintenance therapy following first- or second-line platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Notable examples include the aforementioned GLORIOSA trial (NCT05445778), evaluating MIRV in combination with bevacizumab vs bevacizumab alone as maintenance therapy in patients with FRα-high recurrent PSOC. Additionally, the TroFuse-022 study (NCT06824467) is assessing the efficacy and safety of Sac-TMT, with or without bevacizumab, compared to standard-of-care maintenance following second-line platinum-based doublet chemotherapy. However, in the maintenance setting the important question on which is the best duration of the ADC treatment is still unanswered and will be an important topic for future research. A potential setting for ADC application in ovarian cancer, is after progression to PARP inhibitors, when the rechallenge of platinum-based chemotherapy has limited activity.133,134 For example, in the PICCOLO trial, MIRV in patients with high-FRα PSOC achieved an ORR of 52% in the overall populations and 47% in PARP inhibitors pretreated patients, confirming the treatment with an ADC as a promising option at the time of PARP inhibitors failure.35 New ADC designs Ultimately, the future of ADCs lies with its newer generation. The field is rapidly moving beyond traditional constructs and refining ADC design. Bispecific ADCs (BsADCs) are designed to target two different antigens simultaneously, with the aim of enhancing tumor specificity, addressing tumor heterogeneity, and reducing off-target effects. Currently, ten BsADCs are undergoing clinical trials, and although clinical validation is pending, their implementation could provide opportunities to improve efficacy and bypass mechanisms of resistance.135 The development of BsADCs in gynaecologic malignancies could substantially enhance therapeutic targeting accuracy and this is particularly relevant in ovarian cancer, where biomarker co-expression is common.136 Probody–drug conjugates (PDC) are pharmacologically designed to stay inactive when administered, and are conditionally activated in the tumor microenvironment, thus minimizing systemic toxicity. Activation is triggered by tumor-associated proteases or an acidic environment. Encouraging preclinical experiences have led to the development of an anti CD-166 PDC, with evidence of activity in solid tumors including ovarian cancer.137 Immune-stimulating ADCs (ISACs) are designed to recognize and bind a tumor-specific antigen on cancer cells, but instead of being internalized into cancer cell, are taken up by antigen-presenting cells through interactions with Fcγ receptors. This internalization triggers innate immune responses and enhances T-cell activation, converting immunologically “cold” tumors—such as many ovarian and endometrial cancers—into immunologically active and treatment-responsive tumor microenvironments. These are currently being evaluated in combination with ICIs in early-phase trials.138 Other promising emerging payloads that are immune-activating agents, include the stimulator of interferon genes (STING) agonists. The STING pathway is a critical component of innate immune signaling, driving type I interferon production, dendritic cell maturation, and subsequent activation of adaptive antitumor immunity. Antibody-mediated delivery of STING agonists via ADCs offers a rational approach to localize immune activation within the tumor microenvironment, thereby mitigating off-target toxicity while enhancing antitumor immune responses. In this context, STING-based ADCs function as targeted immunostimulatory agents rather than purely cytotoxic constructs, with the ability to remodel the tumor immune landscape and potentially sensitize tumors to immunotherapy. Dual-payload ADCs involve the incorporation of two or more distinct cytotoxic payloads into a single construct. This strategy addresses key mechanisms of therapeutic resistance frequently observed in gynaecologic tumours, including heterogeneous antigen expression, drug efflux pumps and DNA damage repair proficiency. By delivering complementary payloads with non-overlapping resistance profiles, dual-payload ADCs can induce broader and more durable anti-tumour effects. However, it is important to recognize that dual-payload ADCs may also lead to additive toxicities, which warrant careful clinical development. Currently, dual-payload ADCs are being advanced into clinical trials, while numerous additional dual-payload ADCs are in preclinical development.139,140 Conclusion With growing understanding of tumor biology and increasing preclinical and clinical experience with ADCs, therapeutic opportunities for patients with gynaecologic cancers are improving and the results of ongoing phase III trials are likely to reshape the standard of care treatment (Table S1). Nonetheless, new and complex challenges need to be addressed, including the correct management of new adverse events to maintain patients’ quality of life while improving their outcome. While there is a significant number of ongoing clinical trials, it is important to define predictive biomarkers, understand ADC-resistance, and define the best treatment sequence in order to develop effective, safe, and personalized cancer treatment for patients with gynaecological cancer. Contributors EC: writing-original draft, investigation (literature review). MN: writing-original draft, investigation (literature review). VR: writing-original draft, investigation (literature review), visualitation (figures and tables). HML: writing-review and editing. FM: writing-review and editing. CS: writing-review and editing. IRC: writing-review and editing. KM: writing-review and editing. IC: conceptualisation, supervision, writing-review and editing. Declaration of interests EC: support for attending meetings and/or travelling: GSK; Other, PI for clinical trials (institutional): Lilly. MN: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Abbie, AZ; Support for attending meetings and/or travel: Abbvie. VR: none. HML: other: part-time employment with other institution: Prostate Cancer Research at the Garvan Institute of Medical Research and University of Bern. FM: consulting fees: AZ (personal and institutional), Pharma& (personal), Daiichi Sankyo (personal and institutional), Eisai (personal), Gilead (personal), GSK (personal and institutional), Novartis (personal), Myriad Genetics (personal), Seagen (personal), Steamline Menarini (personal), Lilly (personal), MSD (personal), Pfizer (personal), Roche (personal), Biontech (personal), Nerviano (personal), Bohringer-Ingelheim (personal and institutional); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AZ (personal and institutional), Pharma& (personal), Daiichi Sankyo (personal and institutional), Eisai (personal), Gilead (personal and institutional), GSK (personal and institutional), Myriad Genetics (personal), Seagen (personal), Steamline Menarini (personal and institutional), Lilly (personal), MSD (personal), Pfizer (personal), Roche (personal); Support for attending meetings and/or travel (personal): AZ, GSK, Gilead, Pfizer. Lilly, Stemline, Daiichi Sankyo, Roche, Abbvie; Participation on a Data Safety Monitoring Board or Advisory Board: Immutep, Amgen, Palleos; Other financial or non-financial interests -PI clinical trials (institutional): Roche (Local PI), AZ (coordinating PI), Novartis (Local PI), Roche (Coordinating PI), Eisai (Local PI), Gilead (coordinating PI), MSD (Local PI), German Breast Group (Coordinating PI), AGO Research Gmh (Coordinating PI), Vaccibody (Local PI), GSK (Local PI), Bohringer-Ingelheim, Pfizer, Daiichi Sankyo, Menarini Steamline. CS: Participation on a Data Safety Monitoring Board or Advisory Board: MSD. IRC: grants or contracts: AZ, Clovis, GSK, Mersana, BMS, MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AZ, Clovis GSK, Mersana, BMS, MSD, Roche, Pharmamar, Seagen, Eisai, Novartis, DSI, Abbvie, DSI, Lilly, Tubulis, Genmab; Support for attending meetings and/or travel: Roche, GSK, AZ, Pharmamar, MSD; Participation on a Data Safety Monitoring Board or Advisory Board: Clovis, Deciphera, Adaptimmune, Sutro, Immunogen, Abbvie, DSI, Tubulis, AZ GSK, MSD, Lilly, Scorpion, Antares. KM: Grants or contracts from any entity (research funding, institutional): PTCH Therapeutics, Lilly, Clovis, Genentech, GSK, Verastem; Royalties or licenses: Up to Date (personal); Consulting fees (individual): AZ, Aadi, Abbvie, Biontech, Caris, Dualty, Corcept, Eisai, GSK, Daiichi Sankyo, Immunogen, Jovance, Jansen, Lilly, Mersana, Merck, Novartis, Pharma&, Verastem, Zentalis, Schrodinger, Regeneron, Takeda, Zymeworks, Whitehawk; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (personal): AZ, GSK, Immunogen, PRIME, RTP, Medscape, Great Debates and Updates; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: GOG P Associate Director (personal), GOG Foundation Treasurer (non compensated), ASCO Treasurer (elect). IC: consulting fees (institutional): GSK; consulting fees (personal): Biontech; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Abbvie (institutional), GSK (institutional and personal), Daiichi Sankyo (institutional); Support for attending meeting: GSK; Partecipation in advisory board (institutional): GSK, MSD; Abbvie, Incyte, Beigene; Other, PI clinical trials (institutional): MSD, Incyte, Orion, Vivesto, Tolremo, Debio, AZ, Pharmamar, Bayer. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: vicepresident of the Gynecological Project Group of the Swiss Cancer Institution (unpaid).